- Previous Close
2.9200 - Open
2.8200 - Bid --
- Ask 3.1000 x --
- Day's Range
2.8200 - 2.9000 - 52 Week Range
2.7800 - 5.1000 - Volume
265 - Avg. Volume
7 - Market Cap (intraday)
4.511B - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
47.33 - EPS (TTM)
0.0600 - Earnings Date Apr 23, 2025 - Apr 28, 2025
- Forward Dividend & Yield 0.07 (2.09%)
- Ex-Dividend Date Jun 7, 2024
- 1y Target Est
--
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. In addition, the company offers patient recruitment, investment management, medical registration, pharmaceuticals and regulations consulting, drug safety, bioequivalence, and third-party training services, as well as chemistry, management, and controls services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
www.tigermedgrp.com10,185
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 5HZ1.F
View MorePerformance Overview: 5HZ1.F
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 5HZ1.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 5HZ1.F
View MoreValuation Measures
Market Cap
4.64B
Enterprise Value
4.73B
Trailing P/E
49.56
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.04
Price/Book (mrq)
0.97
Enterprise Value/Revenue
5.71
Enterprise Value/EBITDA
33.37
Financial Highlights
Profitability and Income Statement
Profit Margin
6.14%
Return on Assets (ttm)
2.16%
Return on Equity (ttm)
1.85%
Revenue (ttm)
6.6B
Net Income Avi to Common (ttm)
405.14M
Diluted EPS (ttm)
0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
2.14B
Total Debt/Equity (mrq)
11.77%
Levered Free Cash Flow (ttm)
245.02M